Literature DB >> 27621308

Acute myeloid leukemia with TP53 germ line mutations.

Armin Zebisch1, Ridhima Lal1, Marian Müller1, Karin Lind1, Karl Kashofer2, Michael Girschikofsky3, David Fuchs4, Albert Wölfler1, Jochen B Geigl5, Heinz Sill1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27621308      PMCID： PMC5095760          DOI： 10.1182/blood-2016-08-732610

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  25 in total

Review 1.  Therapy-related myeloid neoplasms: pathobiology and clinical characteristics.

Authors:  H Sill; W Olipitz; A Zebisch; E Schulz; A Wölfler
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice.

Authors:  P Basova; V Pospisil; F Savvulidi; P Burda; K Vargova; L Stanek; M Dluhosova; E Kuzmova; A Jonasova; U Steidl; P Laslo; T Stopka
Journal:  Oncogene       Date:  2013-10-14       Impact factor: 9.867

3.  p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal.

Authors:  Zhen Zhao; Johannes Zuber; Ernesto Diaz-Flores; Laura Lintault; Scott C Kogan; Kevin Shannon; Scott W Lowe
Journal:  Genes Dev       Date:  2010-07-01       Impact factor: 11.361

4.  Puma is required for p53-induced depletion of adult stem cells.

Authors:  Dongping Liu; Linda Ou; Gregory D Clemenson; Connie Chao; Marshall Eli Lutske; Gerard P Zambetti; Fred H Gage; Yang Xu
Journal:  Nat Cell Biol       Date:  2010-09-05       Impact factor: 28.824

5.  Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.

Authors:  Daniel C Link; Laura G Schuettpelz; Dong Shen; Jinling Wang; Matthew J Walter; Shashikant Kulkarni; Jacqueline E Payton; Jennifer Ivanovich; Paul J Goodfellow; Michelle Le Beau; Daniel C Koboldt; David J Dooling; Robert S Fulton; R Hugh F Bender; Lucinda L Fulton; Kimberly D Delehaunty; Catrina C Fronick; Elizabeth L Appelbaum; Heather Schmidt; Rachel Abbott; Michelle O'Laughlin; Ken Chen; Michael D McLellan; Nobish Varghese; Rakesh Nagarajan; Sharon Heath; Timothy A Graubert; Li Ding; Timothy J Ley; Gerard P Zambetti; Richard K Wilson; Elaine R Mardis
Journal:  JAMA       Date:  2011-04-20       Impact factor: 56.272

6.  Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells.

Authors:  O S Kremenetskaya; N P Logacheva; A Y Baryshnikov; P M Chumakov; B P Kopnin
Journal:  Oncol Res       Date:  1997       Impact factor: 5.574

Review 7.  Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.

Authors:  Allison H West; Lucy A Godley; Jane E Churpek
Journal:  Ann N Y Acad Sci       Date:  2014-01-27       Impact factor: 5.691

8.  Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia.

Authors:  Jane E Churpek; Rafael Marquez; Barbara Neistadt; Kimberly Claussen; Ming K Lee; Matthew M Churpek; Dezheng Huo; Howard Weiner; Mekhala Bannerjee; Lucy A Godley; Michelle M Le Beau; Colin C Pritchard; Tom Walsh; Mary-Claire King; Olufunmilayo I Olopade; Richard A Larson
Journal:  Cancer       Date:  2015-12-07       Impact factor: 6.860

9.  p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis.

Authors:  C J Kemp; T Wheldon; A Balmain
Journal:  Nat Genet       Date:  1994-09       Impact factor: 38.330

10.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962
View more
  23 in total

Review 1.  Li-Fraumeni Syndrome Disease Model: A Platform to Develop Precision Cancer Therapy Targeting Oncogenic p53.

Authors:  Ruoji Zhou; An Xu; Julian Gingold; Louise C Strong; Ruiying Zhao; Dung-Fang Lee
Journal:  Trends Pharmacol Sci       Date:  2017-08-14       Impact factor: 14.819

Review 2.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

Review 3.  Role of Germline Predisposition to Therapy-Related Myeloid Neoplasms.

Authors:  Anmol Baranwal; Christopher N Hahn; Mithun Vinod Shah; Devendra K Hiwase
Journal:  Curr Hematol Malig Rep       Date:  2022-08-20       Impact factor: 4.213

Review 4.  Clonal Hematopoiesis: Role in Hematologic and Non-Hematologic Malignancies.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Mediterr J Hematol Infect Dis       Date:  2022-09-01       Impact factor: 3.122

Review 5.  Pediatric Germline Predisposition to Myeloid Neoplasms.

Authors:  Christineil Thompson; Sydney Ariagno; Mira A Kohorst
Journal:  Curr Hematol Malig Rep       Date:  2022-09-19       Impact factor: 4.213

6.  miR-23a mediates resistance to hypomethylating agents in myeloid neoplasms.

Authors:  Marie-Christina Mayer; Johannes Lorenz Berg; Bianca Perfler; Stefan Hatzl; Sereina Annik Herzog; Gerhard Bachmaier; Andrea Berghold; Andreas Reinisch; Albert Wölfler; Heinz Sill; Armin Zebisch
Journal:  Ann Hematol       Date:  2021-07-22       Impact factor: 3.673

Review 7.  Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

Authors:  Jeffery M Klco; Charles G Mullighan
Journal:  Nat Rev Cancer       Date:  2020-12-16       Impact factor: 60.716

Review 8.  Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs.

Authors:  Armin Zebisch; Stefan Hatzl; Martin Pichler; Albert Wölfler; Heinz Sill
Journal:  Int J Mol Sci       Date:  2016-12-10       Impact factor: 5.923

9.  Detection of prognostically relevant mutations and translocations in myeloid sarcoma by next generation sequencing.

Authors:  Karl Kashofer; Max Gornicec; Karin Lind; Veronica Caraffini; Silvia Schauer; Christine Beham-Schmid; Albert Wölfler; Gerald Hoefler; Heinz Sill; Armin Zebisch
Journal:  Leuk Lymphoma       Date:  2017-06-20

Review 10.  Clonal hematopoiesis and risk for hematologic malignancy.

Authors:  Julia T Warren; Daniel C Link
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.